Drug Metabolism & CYP450 Interactions

Drug metabolism shapes nearly every clinical decision in neurology. The cytochrome P450 (CYP) enzyme superfamily handles the bulk of phase I drug metabolism, and the patterns of CYP induction, inhibition, and genetic variability produce most clinically important drug-drug interactions. The neurologist who can quickly identify whether a new prescription will alter the metabolism of existing medications — and whether the patient’s genotype, organ function, or other drugs alter that prescription’s clearance — prevents the majority of preventable adverse drug events. This page covers the major CYP enzymes, the patterns of induction and inhibition, and the practical implications for neurology prescribing.

Phase I vs Phase II Metabolism

Phase I: Functionalization Reactions

• Oxidation (most common): cytochrome P450, monoamine oxidase, alcohol dehydrogenase, xanthine oxidase.
• Reduction.
• Hydrolysis: plasma esterases, amidases.
• Cytochrome P450 (CYP) enzymes are the dominant Phase I system.

Phase II: Conjugation Reactions

• Glucuronidation (UGT enzymes): lamotrigine, morphine.
• Sulfation.
• Acetylation: phenotypic “fast vs slow acetylators” (NAT2 polymorphism); affects isoniazid, hydralazine.
• Glutathione conjugation: detoxifies reactive metabolites.
• Methylation, glycine conjugation.
• Generally produces more water-soluble metabolites for renal excretion.

The Cytochrome P450 Superfamily

Humans have ~57 functional CYP genes; six handle most clinically relevant drug metabolism:

Key CYP Inducers

Drugs that increase the synthesis of CYP enzymes, accelerating metabolism of substrates and reducing their levels:

• Carbamazepine: classical broad inducer of CYP3A4 (and self-induces its own metabolism — “auto-induction” over 2-4 weeks). Reduces effectiveness of: oral contraceptives, warfarin, lamotrigine, valproate, immunosuppressants.
• Phenytoin: broad inducer, similar to carbamazepine.
• Phenobarbital: very broad inducer; long half-life prolongs effect.
• Primidone: metabolized to phenobarbital; inducer.
• Rifampin/rifabutin: potent inducers; problematic in TB co-treatment with neurologic drugs.
• Topiramate: mild inducer of CYP3A4; can reduce oral contraceptive effectiveness at higher doses.
• Felbamate: inducer.
• Oxcarbazepine: mild inducer compared to carbamazepine.
• Eslicarbazepine: mild inducer.
• Cigarette smoke: induces CYP1A2.
• St. John’s Wort: induces CYP3A4 and other enzymes; can reduce many drug levels.

Key CYP Inhibitors

Drugs that block CYP enzymes, decreasing metabolism of substrates and increasing their levels:

• Valproate: inhibits CYP2C9, UGT (glucuronidation); markedly increases lamotrigine levels (50%+); risk of severe lamotrigine rash.
• Fluoxetine, paroxetine: potent CYP2D6 inhibitors; increase TCA, codeine, oxycodone, beta-blocker levels.
• Fluvoxamine: potent CYP1A2 inhibitor; increases caffeine, theophylline, clozapine.
• Sertraline: less potent CYP2D6 inhibitor.
• Cimetidine: broad CYP inhibitor; classic teaching example.
• Ketoconazole, itraconazole: potent CYP3A4 inhibitors; affect many drugs.
• Macrolides (clarithromycin, erythromycin): CYP3A4 inhibitors.
• Ritonavir, cobicistat: very potent CYP3A4 inhibitors; PrEP/treatment for HIV; significant drug interactions.
• Grapefruit juice: CYP3A4 inhibitor at gut level.
• Verapamil, diltiazem: CYP3A4 inhibitors.
• Amiodarone: multiple CYP inhibitor; warfarin, statins, digoxin interactions.

Practical CYP Interactions in Neurology

Lamotrigine

• Glucuronidated by UGT1A4 (not CYP).
• Valproate: inhibits glucuronidation → lamotrigine levels DOUBLE → severe rash risk. Dose: when adding lamotrigine to valproate, start very low (12.5-25 mg) and titrate slowly.
• Carbamazepine, phenytoin, phenobarbital: induce glucuronidation → lamotrigine levels HALVED → need higher dose.
• Oral contraceptives: estrogen induces UGT → lamotrigine levels decrease 50% → may need higher dose; postpartum, levels increase substantially.

Phenytoin

• CYP2C9 and CYP2C19 substrate.
• Saturable kinetics — small dose changes can produce large concentration changes.
• Highly protein-bound; hypoalbuminemia, renal failure → increased free fraction.
• Many interactions: inhibitors (valproate, fluoxetine) and inducers (rifampin) substantially alter levels.
• TDM is standard.

Warfarin

• CYP2C9 substrate; CYP2C19 minor.
• Many interactions: amiodarone, fluconazole, sulfamethoxazole, metronidazole significantly increase INR.
• Carbamazepine, rifampin: induce → decrease INR.
• Vitamin K dietary changes also affect INR.

Clopidogrel

• Prodrug requiring CYP2C19 for activation to active metabolite.
• CYP2C19 polymorphisms produce variable response: poor metabolizers (mainly East Asian populations) have reduced active drug.
• CYP2C19 inhibitors (omeprazole, esomeprazole) can theoretically reduce clopidogrel effectiveness — clinical significance debated.
• Alternative: ticagrelor or prasugrel (different activation pathway).

Codeine and Tramadol

• Codeine: prodrug; CYP2D6 converts to morphine for analgesia.
• Tramadol: CYP2D6 converts to active O-desmethyltramadol.
• CYP2D6 poor metabolizers (~7% of Whites): inadequate analgesia.
• CYP2D6 ultra-rapid metabolizers: increased opioid effect and risk; codeine warning in breastfeeding mothers.

Tricyclic Antidepressants

• CYP2D6 and CYP2C19 substrates.
• Genetic variability and inhibition (fluoxetine, paroxetine) substantially alter levels.

Anti-Epileptic Drug Combination Effects

• Multiple older ASMs (carbamazepine + phenytoin + phenobarbital): heavy enzyme induction; can drop levels of many other drugs (DMTs, anticoagulants, hormones).
• Valproate + lamotrigine: VPA inhibits glucuronidation → lamotrigine accumulation → rash risk.
• Levetiracetam, brivaracetam, lacosamide: minimal CYP interaction; “clean” ASMs.
• Cenobamate: CYP2C19 inhibitor + CYP3A4 inducer; complex interaction profile.

Pharmacogenomic Variation

CYP2D6

• Polymorphic enzyme: poor metabolizers (PMs), intermediate (IMs), extensive (EMs, “normal”), ultrarapid (UMs).
• ~7% of Whites are PMs; ~20% of Asians; lower in African ancestry.
• UMs: very rapid metabolism; codeine over-effect, opioid toxicity.
• Pharmacogenomic testing increasingly used for opioid prescribing.

CYP2C19

• Polymorphism: PMs in ~15% of Asians, 3-5% of Whites.
• Clopidogrel activation: PMs have reduced effect.
• FDA black-box warning for clopidogrel in PMs.
• Genotyping increasingly considered before stroke patient antiplatelet selection.

HLA-B*15:02

• Highly associated with carbamazepine-induced Stevens-Johnson syndrome.
• FDA recommends genetic screening in Asian populations before carbamazepine prescription.
• Other carbamazepine-related severe reactions: HLA-A*31:01 (more diverse populations).

HLA-B*57:01

• Abacavir hypersensitivity (HIV drug).
• Genetic screening standard before abacavir.

UGT1A1*28

• Reduced glucuronidation (Gilbert syndrome).
• Atazanavir, irinotecan dose adjustment.

Non-CYP Metabolic Pathways

Plasma Esterases

• Hydrolyze ester bonds.
• Esmolol (very short half-life), cocaine, succinylcholine.

Aldehyde Dehydrogenase

• Acetaldehyde → acetate.
• Polymorphism in Asians (ALDH2*2) → poor metabolism → “alcohol flush.”

Monoamine Oxidase (MAO)

• MAO-A: serotonin, norepinephrine.
• MAO-B: dopamine (also some PEA, tyramine).
• Inhibitors (selegiline, rasagiline, safinamide for PD; tranylcypromine, isocarboxazid, phenelzine for depression).
• Drug interactions with MAOIs: serotonin syndrome with SSRIs, TCAs; hypertensive crisis with tyramine-rich foods.

Catechol-O-Methyltransferase (COMT)

• Methylates catechols.
• Levodopa → 3-O-methyldopa metabolism.
• COMT inhibitors (entacapone, opicapone, tolcapone) prolong levodopa action.

Practical Clinical Approach to Drug Interactions

1. When adding a new drug, review existing meds.
2. Check both directions: does the new drug interact with existing? Do existing drugs affect new drug?
3. Use drug interaction databases (Lexicomp, Epocrates, online).
4. Anticipate enzyme induction (lag of 1-2 weeks) or inhibition (often immediate).
5. Monitor for clinical effect or measure levels.
6. Educate patient about interaction signs.
7. Consider drug substitution if interaction is severe.

🔍 Did You Know?

The classical interaction of valproate inhibiting lamotrigine glucuronidation is one of the most clinically dangerous drug interactions in neurology — and one that catches even experienced clinicians off guard. Valproate inhibits UGT1A4, the enzyme that conjugates lamotrigine for elimination. The result: when valproate is added to lamotrigine therapy (or lamotrigine is added to existing valproate), lamotrigine concentrations can roughly double. This produces two clinical risks: dose-related side effects (sedation, ataxia, dizziness) and — critically — increased risk of severe cutaneous adverse reactions, particularly Stevens-Johnson syndrome and toxic epidermal necrolysis. The rash risk is highest in the first 4-8 weeks of titration; the higher lamotrigine concentrations from valproate co-administration substantially amplify this risk. The clinical implication: when starting lamotrigine in a patient already on valproate, the starting dose should be reduced (typically 12.5-25 mg daily for the first two weeks, slow titration over 6-8 weeks vs the 4-6 weeks without valproate). When adding valproate to existing lamotrigine therapy, lamotrigine dose should be reduced by approximately 50%. The “rash” warning that lamotrigine carries is meaningful, and valproate co-administration is one of the most consistent risk factors. The lesson generalizes: drug-drug interactions in neurology can be catastrophic when severe cutaneous adverse reactions are at stake, and clinicians should specifically check for known severe interactions whenever combining ASMs.

Pitfalls and Pearls

• CYP3A4: metabolizes ~50% of drugs; many neurology relevant (carbamazepine, statins, benzodiazepines, opioids).
• CYP2D6: 25%; polymorphic; PMs and UMs; codeine, tramadol, TCAs.
• CYP2C9: phenytoin, warfarin, NSAIDs.
• CYP2C19: clopidogrel activation; polymorphic.
• Carbamazepine, phenytoin, phenobarbital: broad CYP inducers; reduce levels of many drugs.
• Valproate: inhibits UGT → lamotrigine accumulation → SEVERE RASH RISK.
• Lamotrigine titration: start very low if on valproate; titrate slowly.
• SSRIs (fluoxetine, paroxetine): CYP2D6 inhibitors; increase TCA levels.
• Grapefruit juice: CYP3A4 inhibitor at gut level.
• HLA-B*15:02: screen before carbamazepine in Asian patients (SJS risk).
• CYP2C19 PMs: reduced clopidogrel response.
• Levetiracetam, brivaracetam, lacosamide: “clean” ASMs; minimal interactions.
• MAOI + SSRI: serotonin syndrome — wait 5 weeks after fluoxetine before MAOI.
• MAOI + tyramine: hypertensive crisis (aged cheese, wine, cured meats).
• Anti-amyloid mAbs + APOE4 homozygosity: high ARIA risk; pre-treatment SWI MRI screening.
• When adding any new drug: review existing meds for interactions.

References

1. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023.
2. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391-396.
3. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring. Epilepsia. 2008;49(7):1239-1276.
4. Brunton L. CYP genotype and stroke patient antiplatelet response: a critical review. Stroke. 2023;54(3):e60-e69.
5. Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm. 2016;73(23):1977-1985.
6. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.